Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05962905 · ClinicalTrials.gov registry record
Accuracy Performance Verification of the INVOS™ System in Pediatrics
A clinical trial, sponsored by Medtronic - MITG.
- Completed
- Registry status
- 110
- Enrollment target
NCT05962905: Completed study, sponsored by Medtronic - MITG.
NCT05962905 is a clinical trial that has completed, run by Medtronic - MITG. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05962905 has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
Prospective, observational, multi-center trial designed to capture calibration and performance evaluation data with the INVOS™ system.
Primary Outcome
root mean square of the difference in regional oxygen saturation (rSO2) as measured by the INVOS and field saturation (fSO2) as measured by blood sampling
Interventions
- OTHER Blood sample
- DEVICE INVOS monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2025-04-30 |
What the finished NCT05962905 record still lists
NCT05962905 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Blood sample is the first listed.
NCT05962905 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05962905 about?
NCT05962905 is a clinical study titled "Accuracy Performance Verification of the INVOS™ System in Pediatrics". Prospective, observational, multi-center trial designed to capture calibration and performance evaluation data with the INVOS™ system.
What is the current status of trial NCT05962905?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2023-11-16. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT05962905?
The interventions under investigation include: Blood sample (OTHER), INVOS monitoring (DEVICE).
Who is sponsoring clinical trial NCT05962905?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI